← Back to Search

TeaCrine and caffeine for Cognitive Impairment

N/A

Waitlist Available

Research Sponsored by University of South Carolina

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up on the experimental visit days: min 0 prior to the exercise protocol, minutes 10, 22, and 30 during the exercise protocol, 5 min after the protocol (min 35), 10 minutes post exercise (min 40)

Awards & highlights

Study Summary

This trial will measure the effects of caffeine, TeaCrine plus caffeine, and a placebo on cognitive performance and heart rate after physical exertion.

Eligible Conditions

Cognitive Impairment
Caffeine
TeaCrine
Hemodynamics

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ on the experimental visit days: min 0 prior to the exercise protocol, minutes 10, 22, and 30 during the exercise protocol, 5 min after the protocol (min 35), 10 minutes post exercise (min 40)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~on the experimental visit days: min 0 prior to the exercise protocol, minutes 10, 22, and 30 during the exercise protocol, 5 min after the protocol (min 35), 10 minutes post exercise (min 40)

This trial's timeline: 3 weeks for screening, Varies for treatment, and on the experimental visit days: min 0 prior to the exercise protocol, minutes 10, 22, and 30 during the exercise protocol, 5 min after the protocol (min 35), 10 minutes post exercise (min 40) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Changes in 2-Back Task

Changes in Anti-Saccade Task

Changes in Attention (Go/No go)

+22 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: TeaCrine and caffeineExperimental Treatment1 Intervention

150mg of Teacrine and 150mg of caffeine

Group II: CaffeineActive Control1 Intervention

300mg of caffeine

Group III: PlaceboPlacebo Group1 Intervention

300mg of cellulose

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

TeaCrine and Caffeine

2023

N/A

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of South CarolinaLead Sponsor

211 Previous Clinical Trials

120,436 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does this research encompass members of the population aged 45 and over?

"This clinical trial is aiming to include participants that are of legal age, between 18 and 45 years old."

Answered by AI

Is it possible to join this investigation?

"Prospective candidates in this medical trial must achieve certain hemodynamic benchmarks and be between 18-45 years old. Currently, the study is recruiting approximately 20 patients."

Answered by AI

Is there still capacity within this research project for participants?

"According to records on clinicaltrials.gov, this study is no longer accepting patients after closing recruitment in February of 2023. However, at the present moment there are 60 other trials that remain open for enrollment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Improving Cognition With Neurodegradation Countermeasure

Shawn M. Arent 2023. "Improving Cognition With Neurodegradation Countermeasure". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05715073.